QIM
ESPR

Quantitative Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Quantitative Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,542
Closed -$300K – 566
2020
Q1 		$300K Buy
+9,542
New +$504K 0.03% 396
2018
Q1 		– Sell
-17,000
Closed -$1.12M – 790
2017
Q4 		$1.12M Sell
17,000
-106,600
-86% -$5.74M 0.02% 589
2017
Q3 		$6.19M Buy
123,600
+42,800
+53% +$2.06M 0.07% 298
2017
Q2 		$3.74M Sell
80,800
-86,100
-52% -$3.17M 0.06% 390
2017
Q1 		$5.89M Buy
166,900
+95,000
+132% +$2.18M 0.09% 299
2016
Q4 		$900K Buy
+71,900
New +$856K 0.02% 624
2016
Q3 		– Sell
-11,300
Closed -$111K – 718
2016
Q2 		$111K Buy
+11,300
New +$187K 0.01% 699
2015
Q4 		– Sell
-17,100
Closed -$403K – 730
2015
Q3 		$403K Buy
+17,100
New +$1.07M 0.03% 486
2015
Q2 		– Sell
-21,500
Closed -$1.99M – 520
2015
Q1 		$1.99M Buy
+21,500
New +$1.39M 0.19% 106

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Quantitative Investment Management's ESPR Position: Q2 2020 in Review

Quantitative Investment Management sold out of Esperion Therapeutics (ESPR) in Q2 2020, closing a stake of 9,542 shares — an estimated $300K sold.

Quantitative Investment Management first reported a position in ESPR in Q1 2015 and held it in 9 quarters. The position peaked at $6.19M in Q3 2017. 182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Quantitative Investment Management reported no remaining Esperion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Quantitative Investment Management sold 9,542 Esperion Therapeutics shares in Q2 2020, an estimated $300K.
  • Quantitative Investment Management first reported a position in Esperion Therapeutics in Q1 2015 and held it in 9 quarters.
  • Quantitative Investment Management's Esperion Therapeutics position peaked at $6.19M in Q3 2017.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Quantitative Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.